Roche Diagnostics Operations, Inc.

University of Toronto

Duke University

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Anthony Gramolini

Georg Hess

Dirk Block

Ursula-Henrike Wienhues-Thelen

Andrew Emili

Peter Liu

David MacLennan

Herbert Von Der Eltz

Hendrik Huedig

Vincent Fong

Ruth Isserlin

Thomas Kislinger

Peter J Mohler

Sara Arab

Hendrik Heudig

Vann Bennett

David Maclennan

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.

Use of IGFBP-7 in the assessment of heart failure

The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.

Use of SLIM-1 in the assessment of heart failure

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.

Use of SFRP-3 in the assessment of heart failure

The present invention relates, generally, to inositol 1,4,5-triphosphate receptors (IP3R), and, in particular, to methods of modulating the activity of 220 kDa ankyrin-B in cellular localization and physiological function of IP3R. The invention further relates to methods of identifying compounds suitable for use in such methods and to compounds so identified.

Methods of modulating localization and physiological function of IP3 receptors

Growing community of inventors

Toronto, Canada

Anthony Gramolini